Viewing Study NCT06256315



Ignite Creation Date: 2024-05-06 @ 8:06 PM
Last Modification Date: 2024-10-26 @ 3:20 PM
Study NCT ID: NCT06256315
Status: RECRUITING
Last Update Posted: 2024-02-13
First Post: 2024-02-05

Brief Title: Hyper-ERAS Program for Highly Selective Colorectal Cancer Patients
Sponsor: Peking University Cancer Hospital Institute
Organization: Peking University Cancer Hospital Institute

Study Overview

Official Title: Hyper Enhanced Recovery After Surgery Hyper-ERAS Program for Highly Selective Colorectal Cancer Patients Undergoing Laparoscopic Surgery
Status: RECRUITING
Status Verified Date: 2024-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This clinical trial aims to explore the safety and effectiveness of the Hyper-ERAS rehabilitation protocol for colorectal cancer patients and the feasibility of discharge within 48 hours
Detailed Description: The Hype-ERAS protocol includes preoperative education intraoperative quality control postoperative preventive analgesia early ambulation early recovery of diet early removal of drainage tube urinary catheter and gastric tube discharge within 48 hours after surgery and standardized follow-up outside the hospital Patients treated with the Hyper-ERAS rehabilitation protocol and discharged within 48 hours were in group A Patients who were treated with Hyper-ERAS protocol and had a postoperative hospital stay of more than 48 hours were classified as group B Patients eligible but not treated with the Hyper-ERAS rehabilitation protocol during the same period were in group C Control group The postoperative recovery of each group was compared to explore the safety and efficacy of Hyper-ERAS rehabilitation program in patients with colorectal cancer

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None